Cereno Scientific announces changes in the nomination committee’s composition for the annual general meeting 2025

Cereno Scientific (Nasdaq First North: CRNO B) (“Cereno Scientific” or the “Company”), announced on May 2, 2024, that the Company’s nomination committee for the annual general meeting 2025 had been appointed and that it consists of Cihan Punar, Joakim Söderström, and Björn Dahlöf. Cereno Scientific today announces that Cihan Punar has informed that he resigns as a member of the Company’s nomination committee and that Andreas Ejlegård has been appointed as new member of the nomination committee.

Cereno Scientific today announces that Cihan Punar has informed that he resigns as a member of the Company’s nomination committee. According to the principles for the nomination committee, the nomination committee shall primarily appoint a new member nominated by the shareholder or the group of shareholders which nominated the resigning member, provided that the shareholder or group of shareholders is still the Company’s largest shareholder or group of shareholders. Cereno Scientific today announces that Andreas Ejlegård has been appointed as a new member of the Company’s nomination committee in accordance with the principles and that he thereby replaces Cihan Punar.

The Company’s nomination committee for the annual general meeting 2025 thus consist of the following members:

• Andreas Ejlegård, representing the Company’s largest group of shareholders per April 30, 2024, and as of today;
• Joakim Söderström, convening member and chairman of the Board of Directors of Cereno Scientific; and
• Björn Dahlöf, CSO and Head of Clinical Development in Cereno Scientific.

The nomination committee’s term of office extends until a new nomination committee is appointed.

For further information, please contact:

Henrik Westdahl, Director IR & Communications
Email: [email protected]
Phone: +46 70-817 59 96

Sten R. Sörensen, CEO
Email: [email protected]
Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for rare and common cardiovascular disease. The lead drug candidate, CS1, is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II trial is ongoing (patient recruitment closed on July 1st, 2024) to evaluate CS1’s safety, tolerability, and exploratory efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). The study will also provide insights for planning the subsequent trial of CS1 in PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the trial. Two initiatives performed during the Phase II trial have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final trial results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno’s pipeline comprises two additional programs in development through research collaborations with the University of Michigan. Investigational drug CS014 is an HDAC inhibitor in Phase I development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without an increased risk of bleeding as documented in preclinical trials. On 28th of June, 2024, Cereno initiated a first-in-human Phase I trial of CS014. Preclinical candidate CS585 is an oral, highly potent and selective IP receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. CS585 was in-licensed from the University of Michigan in 2023. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. Based in Kendall Square, Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). The Certified Advisor is Carnegie Investment Bank AB, [email protected]. More information is on http://www.cerenoscientific.com.